NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NRX Pharmaceuticals Inc (NRXP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has multiple positive catalysts, including favorable FDA developments, strong analyst ratings with high price targets, and a promising market position in the growing ketamine-based therapeutic space. While financial performance shows some weaknesses, the long-term growth potential outweighs these concerns.
The MACD is positive and contracting, indicating a potential upward momentum. RSI is neutral at 61.207, and moving averages are converging, suggesting no strong trend direction. The stock is trading near its pivot point of 2.708, with resistance at 3.132 and support at 2.284.
Positive FDA Discipline Review Letter and expedited approval process for ketamine-based therapies.
Strong analyst ratings with high price targets ($34 and $45).
Favorable U.S. policy shift toward psychedelic therapies, creating a supportive market environment.
Increasing demand for preservative-free ketamine, enhancing market potential.
Weak financial performance in the latest quarter, including a significant drop in net income (-103.97% YoY) and EPS (-101.35% YoY).
Stock trend analysis indicates a 60% chance of minor declines in the short term (-1.2% next day, -1.33% next month).
In 2025/Q4, revenue remained flat YoY at $983,000. However, net income dropped significantly by -103.97% YoY, and EPS fell by -101.35% YoY. Gross margin increased to 54.22%, showing operational efficiency despite weak profitability.
Analysts are bullish on NRXP, with D. Boral Capital assigning a Buy rating and a $34 price target, citing favorable U.S. policy shifts and market positioning. H.C. Wainwright raised its price target to $45, highlighting a de-risked FDA application pathway and expanded addressable population for NRX-100.
